Jubilant Pharmova Limited has reported a strong performance for the financial year ended March 31, 2026. The company achieved consolidated revenue of ₹83,456 million, marking a significant growth over the previous year. Alongside these robust financial results, the Board of Directors has recommended a final dividend of 500%, amounting to ₹5 per equity share, subject to shareholder approval at the upcoming Annual General Meeting.
Financial Highlights
For the financial year ended March 31, 2026, Jubilant Pharmova reported a consolidated revenue of ₹83,456 million, compared to ₹72,913 million in the previous fiscal year. The company demonstrated sustained operational growth, with a net profit for the year standing at ₹3,975 million. The audit reports for both standalone and consolidated financial results have been issued with an unmodified opinion, confirming the integrity and transparency of the financial statements.
Dividend Payout Recommendation
Reflecting the company’s commitment to delivering value to shareholders, the Board has recommended a final dividend of 500%. This translates to ₹5 per equity share with a face value of ₹1. The company has set July 24, 2026, as the record date for the purpose of determining shareholder eligibility for the dividend payout.
Operational Performance and Strategic Outlook
The company’s performance was bolstered by growth across its key business segments. Throughout the year, Jubilant Pharmova navigated various operational challenges, including remediation efforts at its contract manufacturing facilities. The company continues to invest in expanding its capabilities in Radiopharma, Allergy Immunotherapy, and Contract Development and Manufacturing (CDMO) services, which remain core drivers of its long-term strategy.
Future Focus
Management remains focused on maintaining growth momentum while monitoring regulatory and policy changes, such as the new labour code framework. By continuously optimizing its operational footprint and focusing on its high-value research and manufacturing segments, Jubilant Pharmova is well-positioned to drive sustainable growth for its stakeholders in the coming financial year.
Source: BSE
